Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in pancreatic cancer patients

CONCLUSIONS: Our study reveals that neoadjuvant chemotherapy with FOLFIRINOX enhances effector T cells and downregulates suppressor cells. These data indicate that FOLFIRINOX neoadjuvant therapy may improve immune therapy and clinical outcome in PDAC patients.PMID:34593529 | DOI:10.1158/1078-0432.CCR-21-0998
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

ooreman Advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using neoadjuvant chemoradiotherapy, chemotherapy, and immunotherapy have had minimal impact on the overall survival of patients. A general lack of immunogenic features and a complex tumor microenvironment (TME) are likely culprits for therapy refractoriness in PDAC. Induced pluripotent stem cells (iPSCs) should be explored as a means to advance the treatment options for PDAC, by providing representative in vitro models of pancreatic cancer development. In addition, iPSCs could be used for tailor-made cellular immunotherapies or as a source of...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Pathological treatment effect of resected pancreatic adenocarcinoma after neoadjuvant therapy has prognostic implications. The impact for patients who received chemotherapy alone or chemoradiotherapy is not well defined.
Source: Surgery - Category: Surgery Authors: Source Type: research
Ann Surg Oncol. 2021 Nov 1. doi: 10.1245/s10434-021-10991-2. Online ahead of print.ABSTRACTBACKGROUND: Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). The identification of a chemotherapeutic regimen that is both effective and tolerable is critical for NAC to be of oncologic benefit. After initial first-line (FL) NAC, some patients have lack of response or therapeutic toxicities precluding further treatment with the same regimen; optimal decision making regarding this patient population is ...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
Neoadjuvant chemotherapy (NAC) is being utilized more frequently in patients with pancreatic adenocarcinoma (PDAC). Not all patients can tolerate modern multiagent regimens due to toxicity profiles or pre-existing comorbidities. We utilized institutional data and the National Cancer Database (NCDB) to investigate if the time from diagnosis to NAC start is associated with survival from surgery for PDAC.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Hepatobiliary and Pancreas Source Type: research
We have read with interest the seminal publication by Dr Aileen Deng and colleagues, which compared overall survival (OS) based on sequence and type of chemotherapy received in 18,470 patients who underwent surgery for early-stage (stage I or II) pancreatic adenocarcinoma between 2010 and 2014, identified from the National Cancer Database (NCDB) [1]. Five comparison matches – (1) NAT versus upfront resection (UR); (2) multi-agent neoadjuvant (MA NAT) versus single-agent adjuvant therapy (SA AT), single-agent neoadjuvant therapy (SA NAT), multi-agent adjuvant therapy (MA-AT); (3) MA NAT versus MA-AT; 4:...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
AbstractMultimodal treatment including surgery and chemotherapy is considered the gold standard treatment of pancreatic cancer by most guidelines. Neoadjuvant therapy (NAT) has been seen as a possible treatment option for resectable, borderline resectable and locally advanced PaC. The aim of this paper is to offer a state-of-the-art review on neoadjuvant treatments in the setting of pancreatic ductal adenocarcinoma. A systematic literature search was performed using PubMed, Cochrane, Web of Science and Embase databases, in order to identify relevant studies published up to and including July 2021 that reported and analyzed...
Source: Updates in Surgery - Category: Surgery Source Type: research
Formisano Roberto Bianco Patients with locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) do not present distant metastases but are not eligible for surgery upfront. Chemotherapy regimens, such as FOLFIRINOX (FFN) or nab-paclitaxel plus gemcitabine (GemNab) in combination with loco-regional treatments are generally used in this setting. However, the best treatment choice is unknown. We retrospectively analyzed the information of 225 patients with stage II–III PDAC treated at our institution between October 2011 and December 2020. A total of 94 patients with LA PDAC who are non-eligible for surgery u...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: Resistance development in neoadjuvant FOLFIRINOX organoids, recapitulating their primary tumor resistance, suggests continuation of FOLFIRINOX therapy as an adjuvant treatment may not be advantageous for these patients. Gene expression profiles of PDAC organoids identify targetable pathways involved in chemoresistance development upon neoadjuvant FOLFIRINOX treatment, thus opening up combination therapy possibilities.PMID:34580113 | DOI:10.1158/1078-0432.CCR-21-1681
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
ConclusionCompared to historical data, neoadjuvant autophagy inhibition with HCQ plus gemcitabine is associated with encouraging long-term survival for patients with PDAC.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
ierry Conroy Complete surgical resection is the cornerstone of curative therapy for resectable pancreatic adenocarcinoma. Upfront surgery is the gold standard, but it is rarely curative. Neoadjuvant treatment is a logical option, as it may overcome some of the limitations of adjuvant therapy and has already shown some encouraging results. The main concern regarding neoadjuvant therapy is the risk of disease progression during chemotherapy, meaning the opportunity to undergo the intended curative surgery is missed. We reviewed all recent literature in the following areas: major surveys, retrospective studies, meta-analy...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study